Morgan Lewis, Monday Midday, Nov. 16, 2015

Event: “Medicines Pricing and Reimbursement – Demonstrating Value and Sharing Risk in the EU and the US”
Date and time: Monday, November 16, 2015 12:00 pm, Eastern Standard Time (New York)
Duration: 1 hour
Register at https://morganlewis.webex.com/mw3000/mywebex/default.do?nomenu=true&siteurl=morganlewis&service=6&rnd=0.5225169870634279&main_url=https%3A%2F%2Forganlewis.webex.com%2Fec3000%2Feventcenter%2Fevent%2FeventAction.do%3FtheAction%3Ddetail%26confViewID%3D1754138916%26EMK%3D4832534b0000002150e3f7ab9b330c50b81914c1e6e55a70d5fbd663aeae7af00df2c95778b526%26encryptTicket%3DSDJTSwAAAA12DqG-29glB-IQgTAV8R0HHAzbYUDL1ptYvks2fZEGkg2%26siteurl%3Dmorganlewis

Description: In both the European Union and United States, commissioners, regulators, and payers are making increasing evidential demands to show value in relation to the pricing and reimbursement of innovative medicines. Although the mechanisms differ, these demands stem from the same driver—the perceived need to control healthcare product budgets. Join our Washington, DC, and London lawyers and pricing and reimbursement experts for a one-hour webinar to discuss the issues and challenges arising from the growing need in both countries for producers to demonstrate value and share risk.

TOPICS WILL INCLUDE:

- EU-level controls and the consequences of member state autonomy
- Pricing strategies for specialty products and rare diseases in the EU and United States
- Health technology assessment and outcomes research for demonstrating and promoting value
- Risk-sharing agreements, patient access schemes and controls on drug spend
- G2N mandatory discounts and rebates

For more information, please email Rhiannon Pugh at rpugh@morganlewis.com.

Registration is required to join this event. If you have not registered, please do so now.
Date and Time: Monday, Nov. 16, 2015, 6:00 – 9:00 pm
Location: Crowne Plaza Foster City-San Mateo 1221 Chess Drive Foster City, CA 94404
Chair: Ravi Mahalingam, Email: ravichandranooty@yahoo.com, Tel. 209-623-8719
Registration & Payment: Online at http://aaps-badg.org
Advance online registration: working professionals & consultants $50*
AAPS members ( non students ) $45*
Students / Unemployed / Retired $10*
*For on-site registration, add an additional fee of $5 to all levels.
*Registration fee includes a three course dinner and a drink

**************************************************************************************************************
Bio2Device Group, Tuesday Morning, Nov. 17, 2015
Topic: “Ultra-Low-Light CMOS Biosensor Complements Microfluidics to Achieve Portable Diagnostics”
Speaker: Yuping Chung & Zhimin Ding, Founder and CEO, Anitoa Systems
Date and Time: Tuesday, Nov. 17, 2015, 8:30 am
Location: Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyvale, CA
No fee or registration required for morning meetings.

Topic Description
There is currently a strong need for portable and globally affordable molecular diagnostics solutions to help tackle infectious diseases worldwide. Microfluidics alone cannot provide such a solution, unless it is paired as a compact and low-cost read-out instrument. At Anitoa, we introduce an ultra-low-light CMOS biosensor technology, that can compete in sensitivity with the bulky and expensive photon multiplier tubes or cooled charged coupled devices (CCDs) popular in today’s molecular diagnostics instrument, at a much smaller form factor and lower cost. Together with microfluidics, ultra-low-light CMOS biosensors form the backbone of future portable, point-of-care diagnostics platforms.

Speaker Bio
Dr. Zhimin Ding is the founder and CEO of Anitoa Systems, LLC, a provider of biosensors and system solutions for point-of-care molecular diagnostics with offices in Silicon Valley and in Shaoxing, China. He has deep expertise in CMOS System on Chip (SoC) innovations at all levels: process optimization, analog circuitry design and digital signal processing, which jointly contribute to achieving competitive performance. Lately he has been applying these techniques to CMOS-based biosensors in medical applications. Dr. Ding earned a PhD in Electrical Engineering (EE) and Neuroscience from University of Illinois at Urbana Champaign, and Bachelors in EE from Tsinghua University, China.

**************************************************************************************************************
ebAWIS Tuesday Evening, November 17th 2015
Event: “How I got to Now: Leadership Learnings to Nurture Growth and Success”
Speakers: Amita Goel, CEO, Celltheon; Anna Shadman, Vice President, Johnson & Johnson, Janssen R&D; Sheila Babnis, Global Leader, Genentech-Roche
Date and Time: Tuesday, November 17th 2015, 6-8 pm
Location:
Johnson & Johnson, 6500 Paseo Padre Pkwy, Building 1, Fremont, CA 94555
Register Now: https://ebawis-chaptermeeting-leadershiplearnings-nov2015.eventbrite.com
Seats are limited. Please register to reserve your spot.

Event Description
As Professionals, we are interested in continuously learning what it takes to progress, grow and develop in leadership roles. Our impressive panel is comprised of leaders who have worked and led in the corporate continuum, from newly formed start-ups to large company environments.

MedDevice Engineers Bay Area, Tuesday Evening, Nov. 17, 2015

Event: SVEC Open House "Future of IOT: Industrialize and Automate Everything"
Speaker: Mahmood Khan, MBA, PMP, BSc
Date: Nov. 17, 2015: 5:30 pm
Welcome Reception: 5:30pm - 7:00pm
Presentations: 7:00pm - 8:30pm
Agenda:
• Welcoming Remarks
• Keynote Speaker:"Future of IOT(Internet of Things): Industrialize and Automate Everything."
• Report from John J. Kowalchik, VP, Lockheed Martin Space System "Boy Scouts Engineering Explorer Post at Lockheed"
• Acknowledgement of Sponsors
• SVEC Discover "E" Outreach
• Call for Applications for 2016 Scholarships
• 2016 Silicon Valley Engineering Hall of Fame Inductees Announcement
• SVEC Engineers Week Banquet, February 2016
Location: Google (TC6-1-Comic Con), 815 11th Avenue, Sunnyvale, CA 94089

Fee: Complimentary
Please sign up at the attached link.
https://svecopenhouse2015.eventbrite.com

From John Kowalchik:
Lockheed Martin in conjunction with the Boy Scouts of America (Learning for Life) operates an Engineering Explorer Post here at our Sunnyvale facility. This year we had about 50 future engineers and scientists in the program, and we've seen one of our past graduates return as a summer intern this year! We'd like the opportunity to talk about the program in order to encourage other Bay Area companies to consider Exploring as a potential STEM activity. The BSA makes all the logistics very easy and we simply administer the program via our staff engineering folks. It turns out that we're the one and only Engineering Explorer Post in the entire Silicon Valley Monterey Bay area. We'd like to see more.

Event Description
SVEC Open House Reception coming up Nov 17th. Welcome to anyone who would like to attend. Talk on "Future of IOT(Internet of Things): Industrialize and Automate Everything". The SVEC wants to welcome you to our complimentary Annual Open House event! Please pass this invitation along to others you think may be interested. Join us for a complimentary light buffet and an evening of exciting information and engineering camaraderie. Colleagues and spouses are invited to enjoy the festivities.

Speaker Bio
Mahmood Khan has over 18 years of experience in transforming business IT to generate new top line growth, reduce operation costs and improve profit margins. He has held leadership positions at CSC, HP/EDS, IBM-GS as a Client Principal, Practice Director, Solution Architect, and Program/Project Manager. He is a co-founder of G-ESI, an IT Professional Services and training company.
Mahmood is passionate about education and skills training to improving people’s careers and life. He has taught software program development and programming language skills development courses at Berkeley, Santa Cruz Universities and at special events. He is a Board member at San Jose Conservation Corps and Charter School.

BioScience Forum, Wednesday Evening, Nov. 18, 2015

Topic: "Localized Medicines for Localized Diseases"
Speaker: Mathai Mammen, M.D., Ph.D., Senior Vice President, Research and Development, Theravance Biopharma
Date and Time: Wednesday, Nov. 18, 2015, 6:00 – 9:00 pm
6 pm - 7 pm networking
7 pm - 8 pm dinner
8 pm - 9 pm presentation

Location: The Holiday Inn, 275 S Airport Blvd, South San Francisco, California 94080, USA
Price:
Event Registration ($3 service fee will apply)
Pre-Registration $50.00
On-Site Registration $60.00

Register at www.BioSF.org

Topic Description
Medicines delivered by inhalation that are intended to be retained and active in the lung are a useful way of treating certain diseases of the lung. Such medicines avoid systemic exposure, and thereby can potentially be safer than when delivered and absorbed orally. For example, beta2 agonists can be safe and effective bronchodilators for patients with COPD and asthma when delivered by inhalation, but may cause dangerous elevations of heart rate when delivered systemically. However developing a medicine that can be locally administered is challenging, as many of the common principles of drug discovery and development may not apply. More than a decade of success and failure at Theravance Biopharma has allowed the intelligent design of medicines intended for inhalation, with the requisite biological, distributive, and pharmacokinetic properties. The team is applying its insights with an objective of creating inhaled compounds to treat devastating conditions of the lung including idiopathic pulmonary fibrosis and steroid resistant asthma.

Importantly, the opportunities for directing medicines to a specific organ are not limited to the lung. Substantial gains have been made by our team in creating compounds that are taken orally, are absorbed into the wall of the gastrointestinal (GI) tract, distribute through the epithelial cells, lamina propria and associated immune cells, yet have limited absorption into the systemic circulation. The pathway to such GI-directed medicines is remarkably similar to that needed to create inhaled medicines. With this insight, a new modality for GI
medicines is being created, leveraging mechanisms problematic for systemic use. Applications for such medicines include inflammatory diseases of the GI tract such as ulcerative colitis and Crohn’s Disease – diseases that currently require patients to accept significant side effects to be able to manage their disease. The clinical utility of this new class of drugs may not be limited to diseases of the GI tract: with the rapid expansion of our knowledge of the biology of the microbiome, it is plausible that these GI-directed drugs may benefit even systemic diseases. The approaches taken to optimize localized drug delivery will be discussed, along with their potential application to a broad range of diseases.

Speaker Bio
Mathai Mammen, M.D., Ph.D., joined Theravance Biopharma as Senior Vice President, Research and Development, in October 2014. Prior to joining Theravance Biopharma, he co-founded Theravance, Inc. in 1996 and held senior management positions from 2008 to 2014, most recently as Senior Vice President, Research and Development. Previously, he served in various positions in both the Medicinal Chemistry Department and the Molecular and Cellular Biology Departments at Theravance, Inc., most recently as Vice President, Molecular and Cellular Biology.

Dr. Mammen obtained his M.D. from Harvard Medical School/Massachusetts Institute of Technology, and his Ph.D. in Physical Organic Chemistry from Harvard University’s Department of Chemistry working with George Whitesides. Dr. Mammen obtained his Bachelor’s Degree in Chemistry from Dalhousie University in Halifax, Nova Scotia.

*************************************************************************
Palo Alto AWIS, Wednesday Evening, Nov. 18, 2015

Topic: “Bridging the Gap: Communicating Science Broadly”
Moderator: Natalie DeWitt, PhD, is a 15-year veteran of science communications
Panelists:
Monya Baker is a Journalist and Editor at Nature
Crystal Botham, PhD, directs the Biosciences Grant Writing Academy
Tiago Faial, PhD, is an Associate Editor at Nature Genetics
Allison Farrell, PhD, is a Senior Editor at Nature Medicine
Kristin Sainani (née Cobb), PhD, is an associate professor at Stanford University
Nicholas Weiler, PhD, is currently a science writer at UCSF’s news office

Date and Time: Wednesday, Nov. 18, 2015, 7-9 pm
7:00-7:30: Networking dinner
7:30-7:45: Announcements
7:45-9:00: Workshop
Location: PARC Auditorium, 3333 Coyote Hill Rd, Palo Alto, CA 94304
Fees:
Palo Alto AWIS Members: FREE
Pre-registered Non-Members: $10
Fee at Door: $15
Register at http://www.brownpapertickets.com/event/1610910

Topic Description
Effective communication is crucial to successful collaborations, fundraising, and science policy. To help you understand how you can effect change in the scientific and lay community, AWIS has invited Natalie DeWitt to moderate a discussion panel with journal editors, grant writers, and science journalists.

Facilitator Bio
Natalie DeWitt, PhD, is a 15-year veteran of science communications. She has served as a Senior Editor of Nature and Nature Biotechnology and Special Projects Officer to the president of CIRM. More recently, Natalie has founded Accendo Science Editing, an agency offering scientific manuscript and grant
preparation services. She is also an expert consultant for NDA Partners, a global strategy consulting firm that steers medical products industries through product development and regulatory hurdles.

Natalie will facilitate a conversation between you and the panelists about:

- the current state of science communication and publishing
- the importance of the dialog between the scientific community and the public
- gaps that you can fill

The Panelists:

Monya Baker is a Journalist and Editor at Nature. She reports and commissions stories about improving the state of scientific research.

Crystal Botham, PhD, directs the Biosciences Grant Writing Academy and provides individualized grantsmanship support and strategic advice to faculty and postdoctoral scholars in the Division of Cardiovascular Medicine at Stanford.

Tiago Faial, PhD, is an Associate Editor at Nature Genetics, where he is responsible for organizing peer-review and editing of research and news articles. Outside of the office, he enjoys interacting with scientists at conferences and laboratory visits.

Allison Farrell, PhD, is a Senior Editor at Nature Medicine. She pursued received her Ph.D. from the University of California, San Francisco and subsequently joined LeukoSite in Cambridge, MA as a postdoctoral fellow. She did a second post-doc at Harvard Medical School before joining Nature Medicine in 2001.

Kristin Sainani (née Cobb), PhD, is an associate professor at Stanford University. She teaches Statistics and Writing, conducts research in Sports Medicine, and writes about Science and Statistics for a variety of audiences. Her popular Massive Open Online Courses, "Writing in the Sciences" and "Statistics in Medicine" (on OpenEdX) have reached wide audiences.

Nicholas Weiler, PhD, is currently a science writer at UCSF's news office. His prolific activities have included co-founding a Science Communication Network called Neuwrite-West and podcasting for the Science Education Startup Worldview Stanford. Nick is a native of Oakland and lives in San Francisco with his wife, with whom he can be found hiking, cycling, and seeking adventure.

ClinPulse, Wednesday Evening, Nov. 18, 2015

The Expert Event Series BY PRC Clinical
Cheryl Grandinetti, Health Science Policy Analyst / Office of Medical Policy / CDER at Food and Drug Administration; Mary Ann Battles, Head, Clinical Quality & Compliance, Early Development at Genentech; Jim Gearhart, Board of Directors at Quorum Review; Brad Pruitt Chief Medical Officer at Parallel 6; Moderated by: Pierre Corin, Senior Global Project Manager at Genentech
Date and Time: Wednesday, Nov. 18, 2015, 6:00 – 8:30 pm
• 6.00 – 6.45pm | Networking with complimentary food & drinks.
• 6.45 – 7.45pm | Panel Discussion.
• 7.45 – 8.30pm | Networking
Location: Onyx pharmaceuticals, 259 E Grand Ave., South San Francisco, CA
Free event
Register Free And Invite A Friend
ClinPulse, our new Silicon Valley-based panel and networking event series, will focus on the drivers of change in clinical trials. We are gathering subject matter experts to discuss long-term trends and look at ways people are exploring and acting on these themes.

This expert panel discussion and networking event will explore the possibilities, benefits, and challenges of implementing an eConsent process for clinical studies.

How will the eConsent impact the patient experience? How will it improve and streamline the clinical trial process?

What are the different forms of eConsent already available and what lies ahead?

What are the current and upcoming national and international regulatory requirements to implement an eConsent process?

Patients ultimately benefit from the introduction of new therapies, but recruiting and enrolling subjects on time and budget is often easier said than done. With 15-20% of clinical trials never enrolling a single patient, streamlining the subject enrollment process is one of the major challenges ahead for the clinical trial industry.

To better enroll and engage patients, drug developers also need to find the right medium to better explain the objectives and processes at stake in a clinical study.

In that context, the eConsent or electronic informed consent (eIC) is becoming an increasingly hot topic in the clinical trial industry. Earlier this year, the FDA issued a Draft Guidance for using Informed Consent in Clinical Investigations. Shortly after that, Apple announced that its medical research app-builder, ResearchKit, has a module for building electronic consent forms. Even though the ResearchKit doesn’t apply to FDA-regulated studies yet, it is becoming clear that tech giants along with smaller “healthtech” start-ups are increasingly interested in streamlining the clinical trial process.

There are already several types of eSignature and eConsent platforms available, each regulated by a rapidly evolving legal framework. Europe and the rest of the world are in the process of developing a set of requirements to regulate the eConsent process. The protection of patient data privacy and the potential to leverage eConsent technologies around the world are at stake.

Our panel discussion will confront the clinical trial process, the technology, the regulatory landscape, and the patient perspective to understand what lies ahead on “the road to eConsent”.

**********************************************************************

HBA, Wednesday Evening, Nov. 18, 2015

Workshop: “Emotional Intelligence: The New IQ - Creating Personal Success with Emotional Intelligence”
Workshop Leader: Scott Livingston, MBA, EdD, Executive coach and consultant, Livingston Consulting Group
Date and Time: Wednesday, Nov 18, 2015, 5:30 PM - 8:00 PM
Agenda
5:30 - 6:15 PM Registration, reception (appetizers served) and networking
6:15 - 7:45 PM Workshop on emotional intelligence
7:45 - 8:00 PM Close
Location: Genentech (Building 82), 651 Gateway Blvd, 15th Floor, South San Francisco, CA 94080
Registration information
Event is open to: HBA members and nonmembers
Online registration deadline: November 16, 2015
Onsite (walk-in) registration: Is allowed
Member rate:
$35 until November 16, 2015
$45 after November 16, 2015
Nonmember rate:
$45 until November 16, 2015
$55 after November 16, 2015
Genentech employee rate:
$25 until November 16, 2015
$35 after November 16, 2015
Details and registration at http://bit.ly/1H1bax7

Space is limited to 60 registrants.

Cancellations/refunds
Is this event refundable? Yes
If yes, requests must be submitted in writing to events@hbanet.org by November 16, 2015; no refunds are available after this date.

Emotional intelligence enhances decision making and leadership ability. Join us for an interactive workshop hosted by Genentech on how to successfully apply EI for personal and professional success.

Event Type: Program (Education)
Audience: General/All
Primary Competency: 12. Continues to learn, grow and transform
Second Competency: 7. Influences and persuades

Event description
Thinking clearly and using emotion as an advantage can be a powerful tool to achieving both a meaningful career and a life of contentment. Organizations rise or fall in their success based on emotional intelligence.

The key aspects of emotional intelligence are self-awareness, self-mastery, empathy and handling relationships. How in tune are you to what's really important to you? How able are you to manage your own emotions? Understand another person’s feelings? Being able to handle relationships, attune to other people’s moods and persuade others is the mark of great leadership. Emotional intelligence benefits companies and their employees by improving performance through good decision making.

Join Scott Livingston, MBA, EdD, executive coach and consultant, who will lead the workshop and provide you with the tools necessary to access your own EI. Emotional intelligence can be leveraged to enhance your personal success and leadership potential. As a more effective leader, you can enhance the performance of your organization and satisfaction of your clients.

Your program event fee includes: appetizers, venue, networking, and workshop materials

Learning objectives
1. Improve awareness of the impact of emotions on behavior, decision making and judgment
2. Link emotional intelligence to skills such as self-awareness, decision making, and behavioral interviewing
3. Apply EI tools to make better decisions, improve your relationships and lead effectively
EMBS, Wednesday Evening, Nov. 18, 2015

Title: Reimagining the Long-term Homecare Setting with Advanced, Wearable Technology
Speaker: Mark Fauci, Founder and CEO, Gen-9, Inc
Date and Time: Wednesday, November 18, 2015, 7:30 PM
Location: Room M-114, Stanford University Medical School
Optional dinner location: Stanford Hospital cafeteria, 6:15 PM (no host, no reservations)

Topic Description
The strong predilection of most of the elderly, and their families, is to maintain the independence afforded by long-term care delivery in the home rather than in the institutionalized setting. Properly managed, home care can have a significantly positive effect on the quality of care. However, demographic changes are having a profoundly negative impact on the nation's healthcare delivery system and the availability of resources required to meet the challenges of long-term eldercare. One method of mitigating the impact of diminishing human and economic resources in the homecare setting is to augment them with an integrated, technology-based infrastructure optimized for this purpose. We present a wearable technology called the Head-mounted Activity Monitoring (HAM) System. This device possesses functions and a form-factor superior to current wearable systems (Bluetooth headsets, smart watches, Google Glass, etc.), which are currently limited to operating only as accessories to smart mobile devices and performing rudimentary “step counting” functions. We will describe the development of a unique method of accurate indoor tracking relying solely on the data from the MEMS sensors (i.e. no external or internal references such as GPS, WiFi triangulation or vector maps, are used) and machine learning algorithms. We will also describe the HAM System’s capability to perform highly specific anomaly detection that may ultimately be used to predict future events (ex. falls) or the early onset of diseases, thereby providing the opportunity for early intervention and prevention. The system will also provide Web and mobile data access to family and professional caregivers, as well as to medical researchers. This combination of capabilities has not been integrated into a single system before.

Speaker Biography
Mr. Fauci is the founder and CEO of Gen-9, Inc. and brings over thirty years of experience in applied research and commercial product development. As the Principal Investigator on both NIH and DOD funded research projects, he has been responsible for both technology transfer and original innovations as part of his participation in three startups, in two as founder, CEO and CTO, all in the health technology sector. In 2001 he was inducted into NASA’s Space Technology Hall of Fame as an “outstanding innovator that has developed products from space benefiting planet Earth” and was active as an international speaker on the topic of re-missioning aerospace and defense technology for biomedical applications. He holds a B.S.S. from Stony Brook University and an M.B.A. from Dowling College.

HHS Pharmaceutical Forum, Friday, Nov. 20, 2015
Location and Time Friday, Nov. 20 2015, 9:00 – 4:00 pm
It will be held in-person, which requires an invitation, and will also be webcast live. Information re day’s webcast access will be available the week of the conference on the conference website at http://www.hhs.gov/hhspharmaceuticalforum.
Event Description
Modern medicine, including new pharmaceuticals that cure or help combat life threatening diseases, continues to deliver significant benefits for patients. And in general, the development of new, innovative medicines has been good for both patients and our economy. However, the high and growing cost of drugs has created hardship for families, employers, and states. Specialty medications represent only 1% of all prescriptions but, in 2014, these medications resulted in over 31% of all drug spending.
Secretary Burwell is asking stakeholders to share information as to how to address this complex problem. The forum will bring together consumers, providers, employers, manufacturers, health insurance issuers, representatives from state and federal government, and other stakeholders to share information and discuss ideas to increase access to information, drive innovation, strengthen incentives and promote competition.
We seek your views on how to foster a health care system that leads in innovation, delivers the most affordable, highest quality medicines and results in healthier people. During the forum, we will hear from a broad range of stakeholders on opportunities to improve patient access to affordable prescription drugs, develop innovative purchasing strategies and incorporate value-based and outcomes-based models into purchasing programs in both the public and private sectors.
We acknowledge this is a multi-faceted problem with no one solution, but there is a significant benefit – to all of us – of working together to find a solution.

Agenda

<table>
<thead>
<tr>
<th>Time Slot</th>
<th>Agenda Item</th>
</tr>
</thead>
</table>
| 9:00 a.m. – 9:30 a.m. | Welcome & the Impact of Rising Pharmaceutical Costs  
Presenters will discuss the complex problem of rising drug costs, the impact on patients, businesses, taxpayers, and state and federal budgets, and the challenge of balancing innovation with affordability. |
| 9:30 a.m. – 10:30 a.m. | The Balance between Innovation & Smarter Spending  
This session will examine the current and future drug classes that contribute to rising health care costs, as well as the impact of innovative and breakthrough therapies in the pipeline on patient care. |
| 10:45 a.m. – 12:00 p.m. | Patient Access & the Affordability of Prescription Drugs  
The panel will highlight significant challenges for patients and providers in accessing drugs and discuss opportunities to increase access and affordability, and to reward quality of care that drives increased value. |
| 1:00 p.m. – 2:15 p.m. | Purchasing Strategies & Utilization Management Best Practices  
Panelists will share approaches to innovative purchasing strategies, identify best practices within these models, and how the innovations could be implemented in Medicare and Medicaid. |
| 2:30 p.m. – 3:45 p.m. | Value-Based & Outcomes-Based Pharmaceutical Purchasing Programs  
Panelists will discuss value-based and outcomes-based purchasing strategies with a focus on identifying successful elements of these models that can be implemented broadly, and provide some implementation lessons learned from market leaders. |
Please note that lunch and refreshments are not provided; attendees can avail themselves of the Humphrey Building Cafeteria, located on the top floor of the building. There are also a number of express lunch options at the Federal Center SW metro station.

Invitations
Space is limited and attendance is by invitation-only. To request an invitation, to inquire about substitutions, or cancellations, please contact hhspharmforum@mitre.org. Due to space limitations substitutions may not be accommodated.

Special Accommodations
If any of the auxiliary aids or services identified in the Americans with Disabilities Act are required at the conference, please email hhspharmforum@mitre.org prior to arrival.

Travel Information
For those with an invitation that will be attending in-person, the venue will be at HHS in Washington, D.C.. Registration begins at 8:00 a.m. EDT.

The Great Hall
HHS Headquarters
Hubert H. Humphrey Building
200 Independence Ave. SW
Washington, DC 20237

Contact Information
If you have any questions, please contact: hhspharmforum@mitre.org.

*******************************************************

Bio2Device Group, Tuesday Morning, Dec. 1, 2015

Topic: "GPP3 - Establishing Ethical Standards in Scientific Publications"
Speaker: Susy Chen, Medical Director
Date and Time: Tuesday, Dec. 1, 2015, 8:30 am
Location: Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyvale, CA

No registration or cost associated with attending morning meetings

Topic Description
A lot of public scrutiny has been raised over the years regarding industry involvement in scientific publications. GPP (Good publication practice) was developed to place standards to the publication process and address some of the criticisms from public groups. GPP3 is the latest update to the original version. In this presentation we will discuss what GPP represent and what are the changes that occurred with GPP3. This is relevant not only to all those who write or author scientific papers, but to those who read them. Can we count on the information contained in the paper? We shall discuss

Speaker Bio
Susy Chen is a medical doctor with 10 years of clinical practice experience. She also has 10 years of pharmaceutical industry experience. Her experience includes monitoring trials for safety, writing protocols for clinical development programs and Medical Affairs. Her expertise in Medical Affairs is in building departments from the ground up, developing processes and SOPs, hiring and training new team members, planning budget and departmental strategy in alignment with corporate goals. She has managed many publications activities, involving tactical planning and strategy; written and reviewed content for numerous scientific materials

*******************************************************

Seminars at Stanford, Tuesday Midday, Dec. 1 and 3, 2015
PRIME UC, Wednesday Afternoon, Dec. 2, 2015

Event: “Meet UC’s newest top life science spinouts
Date and Time: Wednesday, December 2, 4:30 to 7:30 pm
4:30 pm: Registration opens
5:00 pm: Program begins with keynote by UC President Janet Napolitano
5:30 pm: Quick pitches by the finalists
6:00 pm: Announcement of the winners
6:30 pm: Reception
Location: Byers Auditorium, UCSF Mission Bay
Free
Register at https://www.eventbrite.com/e/primeuc-finals-tickets-19393516530?mc_cid=faf12de73a&mc_eid=cb4c38a44a

Event Description
Launching a company is tough, even at the University of California. Across 10 campuses and three national labs, many UC entrepreneurs would love to get access to the investors and partners who could help them succeed.

To give our entrepreneurs a boost, we created primeUC: a competition that connects UC startups to people who can fuel early-stage growth.

More than 260 entrepreneurs sent in their pitch decks after our August call for entries. Now, in collaboration with Johnson & Johnson Innovation, we’ve picked the top 20. On Wednesday, December 2, the finalists will pitch their companies to a panel that will award $300,000 in prizes.

But no matter which finalists walk away with cash in hand, they’re all winners—primeUC is the stage on which they can unveil their ideas to the world.

Here’s your chance to meet the newest life science spinouts from the University of California! Be part of the excitement. Join us Wednesday, December 2 at UCSF Mission Bay.

CONGRATULATIONS TO THE FINALISTS

- Respirix
- Empire Biotechnologies
- Intact Therapeutics
- FirstStep
- Innovein
- Luma
- SonoMotion
- Laser Associated Sciences
• Spinal Singularity
• Hush
• Glixis
• Biolinq
• D&P BioInnovations
• Cocoon Cam
• TinyKicks
• DermalA
• Magnetic Insight
• Hytek Medical
• Phi Therapeutics
• Hypothermia Devices

JLABS, Wednesday Morning, Dec. 2, 2015

Speaker: Jonathan Norris | Managing Director, Silicon Valley Bank
Date and Time: Wednesday, Dec. 2, 2015, 8:00am
8:00 AM | Registration Opens, Networking
8:30 AM | Presentation and Q&A
9:30 AM | Networking
10:00 AM | Close
Location: JLABS 329 Oyster Point Blvd, 3rd Floor, South San Francisco, California
Fees: $12 | General Public, $8 | Student/Academic

Event Description
2015 has been a wild ride, but how does it compare to 2013 and 2014? What does it take to go IPO and when are acquirers engaging in M&A? This presentation will explore the current state of the BioPharma venture world and include the following topics:
• What does it take to go IPO and when are acquirers engaging in M&A?
• Explore current equity financings vs. the last three years
• Analysis of which venture firms are most active
• The crossover phenomenon and what does it mean for your company?
  - Which crossovers are investing and at which stage
  - Step-up in private equity rounds
  - IPO pre-money valuation and IPO success
  • Exits: the trend to early stage M&A in Biopharma, and explore time to exit, up front and all-in values, and multiples on capital invested by indication.
• IPOs:
  - Types of IPOs completed since 2013 and changes in 2015 to date
  - Average dollars raised and pre money by indication.
At the end of this talk you should be informed as to who is investing in BioPharma and comps for M&A and IPO in your indication.

Speaker Bio
Jonathan Norris | Managing Director, Silicon Valley Bank
Jon Norris is a managing director for SVB’s Healthcare practice. Norris oversees business development efforts for banking and lending opportunities as well as spearheading strategic relationships with many healthcare venture capital firms. He also helps SVB Capital through sourcing and advising on direct equity co-investment
and limited partnership allocations. In addition, he has authored numerous thought leadership pieces examining the flow of capital into healthcare, including detailed analysis of venture-backed M&A and IPOs. Norris has more than thirteen years of banking experience working with life science companies and venture capital firms. Prior to joining SVB Capital, Norris was a founding member and senior vice president of Square 1 Bank, an early stage technology bank, where he was responsible for sourcing deals and managing regional and national venture capital relationships. Norris also served more than six years at Imperial Bank (subsequently acquired by Comerica Bank), most recently as senior vice president and group manager of the Northern California Life Science Practice. Prior to banking, Norris was a practicing litigation attorney, specializing in employment defense and toxic tort litigation. Norris earned a bachelor's degree in business administration from the University of California, Riverside and a juris doctorate from Santa Clara University.

About John: Norris spends most of his non-banking time with his family in Los Altos, attending and coaching many youth sports. An avid baseball fan, he still plays baseball in a men's baseball league in San Jose.

PBSS Workshop, Friday Afternoon, Dec. 4, 2015

Speakers: Janet Xiao (Morrison & Foerster LLP), Jen Liu (Orrick, Herrington & Sutcliffe LLP), Vandana
Date and Time: Friday, December 04, 2015, 12:45-17:30
Location: SF Bay Area: Foster City Crowne Plaza
Registration fee (US$): Regular: $125; For unemployed & students: $20; For major-sponsor rep (incl lunch): $0; For vendor-show reps: $25; For others, details available upon online login.
Registration: [http://www.PBSS.org](http://www.PBSS.org)
Further Information:
Registration deadline: 12/3/2015 (it will close sooner if the seating cap is reached)

About the Topic
This workshop aims to help life science professionals gain good understanding on the business values of patents and the process of building a strong patent portfolio. The workshop will begin with an overview of key factors for building a strong patent portfolio in the life science industry. Basic legal requirements for patentability, as well as recent changes in patent law that impact patent strategic considerations will then be covered. With this groundwork, we will then discuss the process and key considerations for obtaining patent protection from the inception of the ideas to the preparation of a patent application and working with the patent office to obtain a patent. The workshop will conclude with an overview of the key considerations during IP due diligence as well as practice tips on how to best prepare life science companies for IP due diligence by investors and collaborators. Real-life case studies will be presented throughout the workshop.

Key topics to be covered:
- Business values of a strong IP portfolio; what constitutes a strong IP portfolio and how to build one
- Legal requirements for patentability and recent changes in patent law impacting patent strategic considerations
- Overview and key considerations of the patent application process
- IP due diligence practice and practice tips on how best to prepare for IP due diligence
Speaker Bios
Dr. Janet Xiao is a partner in Morrison & Foerster’s Life Science Group primarily representing clients in the biotechnology and pharmaceutical industries in their world-wide patent procurement, patent portfolio management, and strategic planning. Dr. Xiao advises biopharmaceutical companies and research institutions on patent matters relating to various technologies including antibody therapeutics, nanomedicine, personalized medicine, drug delivery systems, drug screening platforms, diagnostics, and nutraceuticals. She also represents many start-up biopharmaceutical companies to help them build a strong IP position from inception. In both 2014 and 2015 Dr. Xiao was listed in Chambers Global as a leading IP expert in the U.S. and a leading IP lawyer in China as an expert based abroad. Ms. Zheng (Jen) Liu, Of Counsel in the Silicon Valley office of Orrick, Herrington, & Sutcliffe LLP, is a member of her firm’s Intellectual Property Group. Ms. Liu’s practice focuses on patent, trade secrets, and unfair competition litigation, intellectual property counseling, due diligence and technology transactions across a broad range of industries, including biotechnology, pharmaceutical, medical devices, Internet and telecommunications. Ms. Liu has also been the lead member for many patent infringement and commercial litigation cases and has argued important issues such as claim construction and examined witnesses in federal courts.

RAPS, Friday Evening, Dec. 4, 2015

Topic: “CAPAs, Complaints and Design Control: Lessons Learned from Audit Findings”
Date and Time: Friday, Dec. 4, 2015
Location: Crowne Plaza, Foster City, CA

Topic Description
In this one-day conference, FDA, Notified Body and industry experts will explore three regulatory areas where device and diagnostic companies often miss the boat:

- CAPAs
- Complaints
- Design Control

Regulators and industry experts will examine what’s wrong and discuss how to do it right. This meeting will benefit regulatory, quality and R&D personnel from device and diagnostic companies. In a bonus segment, a Notified Body Director provides insight into an auditor’s focus during the MDSAP process.

This meeting will benefit regulatory, quality and R&D personnel from device and diagnostic companies. In a bonus segment, a Notified Body Director provides insight into an auditor's focus during the MDSAP process.

Registration will open in the coming weeks, so mark this date on your calendar now.

Bio2Device Group, Tuesday Evening, Dec. 8, 2015

Topic: “Vaccines, Canaries and Coalmines: What lessons for Biopharma from the Oldest Class of Biologics?”
Speaker: Piers Whitehead, Special Advisor to the CEO, Acquisitions, PaxVax
Date and Time: Tuesday, Dec. 8, 2015, 6:00 pm
Location: Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto CA
Cost:
$6 - Students/In-transition - Members only
$11 - Early-bird Registration - Members only
$20 - Late Registration and Non-Members
$25 - Walk-ins
Register at www.Bio2DeviceGroup.org

Topic Description
Since at least the 15th Century, people have been vaccinating against infectious disease. As the most "mature" biopharma sector, what can we learn from it about broader biopharma trends, such as industry concentration, the role of developing country producers, achieving global access, industry cycles and more?

Speaker Bio
Mr. Whitehead joined PaxVax in early 2013 and brings 20 years of experience in the vaccines and biopharmaceutical industries. He previously served as Vice President of Corporate Development for Paris-based Neovacs. Prior to that, he was Vice President of Corporate and Business Development for vaccine company, VaxGen. At VaxGen, he negotiated several important partnerships and led the company’s commercial strategy, resulting in the award of a nearly one billion dollar Project Bioshield Act contract. He also spent 10 years at Mercer Management Consulting, where he headed the San Francisco office and led marketing, strategy, and manufacturing projects for clients including the Global Alliance for Vaccines and Immunization (GAVI), UNICEF, and several private-sector pharmaceutical and biopharmaceutical companies. Mr. Whitehead has published extensively on the vaccine industry and related public policy matters and holds an A.B. from Oriel College, Oxford University, England.

*******************************************************************
WIB, Tuesday Evening, Dec. 8, 2015

Event: WIB-San Francisco Bay Area Holiday Party
Date and Time: Tuesday, December 8, 2015, 6:00 p.m. – 9:00 p.m. PST
Registration Deadline
December 6, 2015
Location: Devil’s Canyon Brewing Company, 935 Washington Street, San Carlos, CA 94070
Pricing Information
Members: $25
Non-Members: $45

Topic Description
Come join WIB-San Francisco Bay Area chapter members at Devil’s Canyon Brewing Company on December 8th to celebrate another phenomenally successful year. None of this would have been possible without the untiring support of our amazing volunteers. Let us say, "Thank You," to them and wish WIB continued success.

To take advantage of a free subscription to WIB-Smartbrief, a weekly newsletter that will keep you updated about women making a difference in biotech and life sciences, please sign up here.

Address:
SanFrancisco@WomenInBio.org

*******************************************************************
Seminar At Stanford, Mid Day, Thursday, Jan. 14, 2015

Topic: "Cell Survival Under Starvation"
PRE-SEMINARS IN CLARK CENTER ROOM S361; SEMINARS IN CLARK CENTER ROOM S360
Small Lunch Served At 12:00; Lectures Begin At 12:15
Pre-Seminars In Clark Center Room S361; Seminars In Clark Center Room S360
Pre-Seminar Speaker: Kang Shen, Departments Of Biology And Pathology
Seminar Speaker: Jennifer Lippincott-Schwartz, NIH

Date And Time: January 14, 2016, 12 Noon

PBSS Workshop, Friday, Jan. 22, 2015

Date: Friday, January 22, 2016; 8:45-17:00
Location: SF Bay Area: Foster City Crowne Plaza
Registration fee (US$): For unemployed & students: $30; For vendor-show rep: $35;
Regular: $195; For major-sponsor rep (incl lunch): $0;
Registration: http://www.PBSS.org
Registration deadline: 1/20/2016 (it will close sooner if the seating cap is reached)

PMWC, Monday – Wednesday, Jan. 24-27, 2015

Event: Personalized Medicine World Conference
Date and Time: Monday, January 25, 2016 at 7:00 AM -Wednesday, January 27, 2016 at 5:00 PM (PST)
Location: Computer History Museum 1401 N Shoreline Blvd
Mountain View, CA 94043
See program details at http://2016sv.pmwcintl.com/all/
Price: $1,000 prior to Oct. 15 and then $2,500 through Jan. 24, 2015
Register at https://www.eventbrite.com/e/pmwc-2016-sv-attendees-tickets-14926919819

Event Description
The Personalized Medicine World Conference (PMWC) is the only fully integrated conference to examine the advances and challenges of Personalized Medicine through a practical lens. PMWC brings together the thought-leaders of business, government, healthcare-delivery, research and technology into one information-rich, two-day conference.
Tickets are not refundable!
These individuals all have played, and continue to play, tremendously critical roles in shaping the human healthcare system, changing it from a general population approach to a personalized and patient-centered care model. For this reason, their outstanding contributions to medicine will be recognized by awarding them the Pioneer and Luminary Awards at the upcoming Personalized Medicine World Conference 2016 Silicon Valley on January 24-27.

The Luminary Awards will be presented to Dr. Roger Perlmutter for transforming two R&D organizations and for the development of groundbreaking new therapies, and to Dr. Esserman for her visionary approach towards breast cancer medicine.

The Pioneer Awards will go to Dr. Ralph Snyderman, referred to as the “father of personalized medicine”, and to Dr. Irv Weissman, similarly referred to as the “father of hematopoiesis”.

Join 1,100 peers in Silicon Valley on January 24 - 27, 2016
With more than 65 sessions, 130 speakers and three parallel tracks

Building on the groundwork for transformative patient-centered health care at PMWC 2016 Silicon Valley

The adoption of personalized medicine is being driven by a multitude of advancements across different disciplines that thrive on technological innovations. Next-generation sequencing (NGS), computational power and mechanism-based biology are all contributing to better disease diagnosis, prognosis and treatment. As such, more and more individuals undergo NGS-based diagnostic testing, primarily in the area of oncology. With these advancements and the President’s Precision Medicine Initiative it is expected that in the near future we not only see larger populations getting tested, but also having their DNA fully sequenced.

The value of NGS in this context is indisputable and as such we can observe a strong interplay with the clinic — clinical adoption drives innovation even as NGS drives new applications. As NGS adds to the identification and application of new biomarkers, contributes to the understanding and characterization of the underlying biology of human diseases, and aids in the identification and characterization of new drug targets, a number of non-trivial challenges arise, such as increasing complexity in clinical trial design and patient selection, and increased pressure to provide justification of clear clinical value to both payers and patients.

The tenth Personalized Medicine World Conference (PMWC 2016), which will take place from January 24 - 27 in Silicon Valley, will focus on these developments in a collegial setting that fosters scientific exchange, networking and partnering. The broad array of topics covered span biological, engineering and computational advancements as well as research and commercial applications, and the conference will touch upon issues such as data privacy and security, regulatory updates and commercial opportunities. Lastly, a panel on “NGS & Clinical Interplay” will provide multi-faceted perspectives from Helix’s new CEO, Peter Yu (ASCO), Cliff Reid (Complete Genomics), Rick Klausner (Illumina), Allison Ballmer (Roche), Jonas Korlach (PacBio) and others.

For more, visit us at: http://2016sv.pmwcintl.com
Follow us on Twitter to get more updates: @PMWCintl

LUMINARY AWARD RECIPIENTS

Laura Esserman, MD, MBA, is a recognized breast surgeon and breast oncology specialist at the University of California, San Francisco leading a groundbreaking national public-private collaboration combining personalized medicine with a novel trial design, which has now become the new model for translational research. Dr. Esserman is currently focusing on a 100,000 women breast cancer screening study to determine whether a personalized approach to screening and treatment is safer and more effective. Read Full Bio

Roger M. Perlmutter, MD, Ph.D, (President, Merck Research Laboratories and previously Amgen) transformed two major R&D organizations and enabled the
expeditious development and subsequent approval of small molecule and biologic medicines including the monoclonal antibody Denosumab (for the treatment of osteoporosis) and the anti-PD1 therapy, Keytruda, to treat metastatic melanoma.

PIONEER AWARD RECIPIENTS

**Ralph Snyderman, MD** (Chancellor Emeritus, Duke University and James B. Duke Professor of Medicine in the Duke University School of Medicine), who has created a transformative environment to improve our nation’s health over the last 40 years. During this time, he led the transition of the School of Medicine at Duke University into a globally recognized leader of academic medicine and played a leading role in the conception and development of Personalized Health Care, an evolving model of national health care delivery. He was amongst the first to envision and articulate the need to move the current focus of health care from the treatment of disease-events to personalized, predictive, preventive, and participatory care that is focused on the patient.

**Irv Weissman, MD** (Director of the Institute of Stem Cell Biology & Regenerative Medicine at Stanford School of Medicine), contributed to the understanding of hematopoiesis and moved the field of stem cell research forward to make successful treatments a reality. Not only was he instrumental in isolating the first blood-forming stem cells in mice and humans early on, he is also recognized for isolating human Leukemia cancer stem cells. His work and discoveries on stem cell aging contributed to the understanding of cancer stem cells and the immune system and are pioneering achievements with far-reaching clinical applications.

******************************************************************

**JLABS, Tuesday Morning, Jan. 26, 2015**

Event: Meet with...Canaan Partners  
Speaker: Wende Hutton | General Partner, Canaan Partners  
Date and Time: Tuesday, Jan. 26, 2015, 10:30 am – 1:00 pm  
Location: Johnson & Johnson Innovation, JLABS, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California  
Fees:  
Presentation & Lunch  
$25 | General Public  
$35 | General Public Onsite  
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain open until January 25th, 2016 (or sold out).

One-on-One Meeting  
FREE | Application  
FREE | Accepted Companies  
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ends on December 1st, 2015. Your application will be reviewed and you will be notified of acceptance by January 5th, 2016. Acceptance of a one-
on-one meeting is not guaranteed as all applications must be approved.

Register at http://www.eventbrite.com/e/meet-with-canaan-partners-tickets-18496128418?aff=blast#s1

Event Description
Canaan Partners is a global venture capital firm that invests in entrepreneurs with visionary ideas. With $4.2 billion under management and over 180 exits to date, Canaan has funded some of the world's leading technology companies including LendingClub, Ebates, PrimeSense, and Skybox Imaging as well as healthcare stars like Chimerix, Durata, Labrys Biologics, and Civitas Therapeutics. Canaan recently announced Fund X, a $675 million fund focused on early stage IT and healthcare startups. The fund's healthcare focus inclu

Wende Hutton, General Partner, will be in attendance on January 26th to provide an overview presentation of Canaan's areas of interest and best practices when applying for funding. Following the presentation, don't miss this opportunity to introduce yourself to Wende during the networking lunch. And finally, for those companies who apply online and are approved, one-on-one meetings with Wende will provide a forum to discuss your company.

Speaker Bio
Wende Hutton | General Partner, Canaan Partners
Healthcare investor Wende Hutton brings 20 years of experience to identifying, investing in and building companies that are changing the practice of medicine. She has facilitated bringing over a dozen medical devices and drugs to market, and currently sits on the boards of Butterfly Health, Chrono Therapeutics, Dermira, Glooko, ReVision Optics, Theraclone Sciences and Transcend Medical. Prior investments include BiPar Sciences (acquired by Sanofi-aventis), Chimerix (CMRX), and Labrys Biologics (acquired by Teva Pharmaceutical). Wende was recognized among Fierce Biotech's 2014 "Fierce 15" women in biotech and honored as one of The Most Influential Women in Bay Area Business 2015 by The San Francisco Business Times. Wende joined Canaan in 2004, and her life sciences track record includes seven IPOs and five acquisitions. She began her venture career at Mayfield Fund in 1993, where she worked closely with the founding teams of Heartstream (HPQ) and Northstar Neuroscience (NSTR). Earlier in her career, Wende held senior operational management positions at GenPharm International and Nellcor in business development and marketing. Wende holds an AB in human biology from Stanford University and an MBA from Harvard Business School, where she was a Baker Scholar. She is active with several community service groups including serving on the board of FACE AIDS.

Seminar at Stanford, Mid Day, Feb. 9, 2015

Topic: "Novel Technologies to Investigate the Stem Cell Niche"
Date and Time: Feb. 9, 2015, 12:00 pm
Location: Pre-Seminars In Clark Center Room S361; Seminars In Clark Center Room S360
Event Details:
Small Lunch Served At 12:00��; Lectures Begin At12:15��
Pre-Seminars In Clark Center Room S361; Seminars In Clark Center Room S360
February 9, 2016
Pre-Seminar Speaker: Michael Lin, Departments of Pediatrics and Bioengineering
February 11, 2016
JLABS, Thursday, Feb. 26, 2016

Topic: “Meet with....Sofinnova Ventures”
Speaker: Mike PowellSofinnova Ventures Participating Representative
Date and Time: Thursday, Feb. 26, 2016; 10:30 am to 1:00 pm
Agenda:
10:30am | Registration Opens and Networking
11:00am | Presentation and Q&A
11:45am | Networking Lunch
1:00-5:00pm | One-on-one Meetings*

*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ends on January 25th, 2016.
Location: Johnson & Johnson Innovation, JLABS, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California

Fees:
Presentation & Lunch
$25 | General Public
$35 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain open until February 24th, 2016 (or sold out).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ends on January 25th, 2016. Your application will be reviewed and you will be notified of acceptance by February 11th, 2016. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.

Topic Description
Are you Sofinnova material? Sofinnova Ventures, a leader in funding for life sciences companies, is visiting Johnson & Johnson Innovation, JLABS. With $2 billion under management and a recent $500 million fund, Sofinnova is looking to invest in life science innovators. Focus areas include clinical drug development and drug discovery.

Since 1974, Sofinnova has partnered with entrepreneurs to secure initial funding, build successful management teams, form impactful corporate alliances, win key customers, and navigate acquisitions and IPOs. Sofinnova applies capital and expertise to guide start-up companies to successful exits. Recent exits include Labrys Biologics, Tesaro, and Spark.

Representatives from Sofinnova will be in attendance to give an overview presentation about the company’s key areas of interest and best practices when seeking startup funds. Following the presentation, don't miss this opportunity to
introduce yourself to Mike Powell, General Partner, during the networking lunch. And finally, for those companies who apply online and are approved, one-on-one meetings with Sofinnova will provide a forum to discuss your company.

Speaker Bio
Mike Powell, Ph.D. | General Partner, Sofinnova Ventures
Mike joined Sofinnova in 1997, and SVP IX ($510M) is his sixth Sofinnova fund. He has 32 years of experience, including 15 years of R&D before venture. Mike has been involved in more than 50 clinical programs, and is the author of 90 publications and books, including a 1,000-page treatise on vaccine design. He was the initial venture investor of: Actelion (ATLN), InterMune (ITMN), Orexigen (OREX), Seattle Genetics (SGEN), Threshold (THLD), and Trius (TSRX) and other public and private companies such as Intellikine (sold to Millennium-Takeda), Mirna and Labrys Biologics (sold to Teva). Mike was the first person in the biotech industry to be honored by the American Association of Pharmaceutical Scientists as an AAPS Fellow. He has also served on the journal editorial boards of Journal of Pharmaceutical Sciences and the Journal of Controlled Release. He has been the Board President of the AIDS Vaccine Advocacy Coalition, as well as advisor to the Institute for One World Health, IAVI, and the Bill and Melinda Gates Foundation. Mike is also Adjunct Associate Professor in the Department of Pharmaceutical Chemistry at the University of Kansas, one of the top US pharmacy schools. Before joining Sofinnova, he was group leader of drug delivery at Genentech. During his tenure there, he and colleagues spun off VaxGen, an AIDS vaccine company. Prior to Genentech, he helped start Cytel as the Director of Product Development. Before this he was Senior Scientist and Project Team Leader at Syntex Research. Mike received his PhD in Chemistry from the University of Toronto and carried out postdoctoral studies in bio-organic chemistry at the University of California as a National Science and Engineering Research Council Scholar. Mike and his wife Tana live in San Francisco, and they enjoy flying, skiing, diving and flyfishing.
Connect with Mike: Connect on LinkedIn

Bio2Device Group, Tuesday Evening, August 9, 2016

Topic: TBA
Speaker: Dr. Allison Dupuy, Partner, Simon-Kucher
Date and Time: Tuesday, Aug. 9, 2016, 6:00 pm
Date and Time: Tuesday, Oct. 13, 2015, 6:00pm
Location: Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto CA
Cost:
$6 - Students/In-transition - Members only
$11 - Early-bird Registration - Members only
$20 - Late Registration and Non-Members
$25 - Walk-ins (as space permits)
Register at www.Bio2DeviceGroup.org

Speaker Bio
Dr. Allison Dupuy is a Partner in the Life Sciences division of Simon-Kucher & Partners in San Francisco and leads the company’s life sciences practice on the west coast of the US. She joined the team in San Francisco in August 2012 after spending 5 years in Simon-Kucher’s Boston office.
In her work at Simon-Kucher, she focuses on strategic pharmaceutical marketing, value-to-customer, market entry strategies, pricing and market access strategies, innovative
pricing strategies, product lifecycle strategies, licensing and valuation, market forecasting and value communication, including global value story development and implementation. She is a trusted advisor of leading pharmaceutical and biotech companies across a wide range of therapeutic areas in all major healthcare markets across the globe.

Dr. Dupuy received her Ph.D. and M.Phil. in Molecular Biophysics and Biochemistry from Yale University and a B.A. in Physics with honors from Wellesley College where she was a Goldwater Scholar and a Schiff Fellow. She is the author and coauthor of several scientific publications and has research experience in theoretical and experimental physics, biophysics, cell biology, cancer biology, genomics, proteomics, bioinformatics and biochemistry.